Fresh analysis suggests that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Published data in a prominent health publication shows that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing these treatments need to be aware of the danger of fast weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting mass in about 18 months.
Analyzing Therapies
The research, which examined dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
Scientists note that people who shed pounds through lifestyle changes alone generally have a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Nutrition scientists believe the way of the injections accounts for the amplified weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal might result in the body to produce less of its own natural hormone, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in appetite is unsuppressed, making binge eating far more likely."
A Chronic Disease?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the high risk of weight regain, the therapy should be considered ongoing.
This opinion is echoed by drug manufacturers, who state that the findings "highlight the chronic nature of obesity," comparing it to managing diseases like hypertension.
User Testimonies
Individuals who have stopped the jabs explain a sudden resurgence of appetite.
"I experienced a switch that goes on and I was suddenly starving," recalled one woman.
This challenge is exacerbated if users have not adopted sustainable lifestyle or habit modifications during treatment.
Growing Interest
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is greater among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and lasting health benefits relies on ongoing behavioural support.
